Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants

Pharmacogenetics and Genomics

Volumn 21, Issue 9, 2011, Pages 539-551

  Erickson Ridout, Kathryn Kelly ^a   Zhu, Junjia ^a   Lazarus, Philip ^a,b  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENN STATE CANCER INSTITUTE   (United States)

Author keywords

metabolism; olanzapine; UDP glucuronosyltransferases; UGT1A4; UGT2B10; variant alleles

Indexed keywords

DRUG METABOLITE; GLUCURONIDE; GLUCURONOSYLTRANSFERASE; GLUCURONOSYLTRANSFERASE 1A4; GLUCURONOSYLTRANSFERASE 2B10; OLANZAPINE; OLANZAPINE 10 N GLUCURONIDE; OLANZAPINE 4' N GLUCURONIDE; UNCLASSIFIED DRUG;

ALLELE; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME KINETICS; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN TISSUE; ISOMER; LIVER MICROSOME METABOLISM; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ULTRA PERFORMANCE LIQUID CHROMATOGRAPHY; WESTERN BLOTTING; WILD TYPE;

EID: 80051792894     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e328348c76b     Document Type: Article

References (56)

1. FDA. Electronic Orange Book. 2011 6/10/2009 (cited 2009 3/10/2009); Available from: http://www.accessdata.fda.gov/scripts/cder/ob/default.cfm
2. Katz R. NDA 21-520. Indianapolis: Food and Drug Administration; 2003.
3. Katz R. NDA 20-592/S-019. Indianapolis: Food and Drug Administration; 2004.
4. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003;290:2693-2702. (Pubitemid 37475597)
5. Kahn RS, Fleischhacker WW, Boter H, Davidson M, Vergouwe Y, Keet IP, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-1097. (Pubitemid 351418005)
6. Lehman AF, Lieberman JA, Dixon LB, McGlashan TH, Miller AL, Perkins DO, et al. Practice guideline for the treatment of patients with schizophrenia, second edition. Am J Psychiatr 2004;161(2 Suppl):1-56.
7. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-1223. (Pubitemid 41345943)
8. Komossa K, Rummel-Kluge C, Hunger H, Schmid F, Schwarz S, Duggan L, et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010;3:CD006654.
9. Gothelf D, Falk B, Singer P, Kairi M, Phillep M, Zigel L, et al. Weight gain associated with increased food intake and low habitual activity levels in male adolescent schizophrenic inpatients treated with olanzapine. Am J Psychiatry 2002;159:1055-1057. (Pubitemid 34586957)
10. Kinon BJBB, Gilmore JA, Tollefson GD. Longterm olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100. (Pubitemid 32199865)
11. Wirshing DA, Wirshing WC, Kysar L, Berisford MA, Goldstein D, Pashdag J, et al. Novel antipsychotics: comparison of weight gain liabilities. J Clin Psychiatry 1999;60:358-363. (Pubitemid 29289721)
12. Parsons B, Allison DB, Loebel A, Williams K, Giller E, Romano S, et al. Weight effects associated with antipsychotics: a comprehensive database analysis. Schizophr Res 2009;110:103-110.
13. Rosenheck RA, Davis S, Covell N, Essock S, Swartz M, Stroup S, et al. Does switching to a new antipsychotic improve outcomes? Data from the CATIE trial. Schizophr Res 2009;107:22-29.
14. Monteleone P, Martiadis V, Maj M. Management of schizophrenia with obesity, metabolic, and endocrinological disorders. Psychiatr Clin North Am 2009;32:775-794.
15. Laurent S, Boutouyrie P. Arterial stiffness and stroke in hypertension: therapeutic implications for stroke prevention. CNS Drugs 2005;19:1-11. (Pubitemid 40165153)
16. Wu TH, Chiu CC, Shen WW, Lin FW, Wang LH, Chen HY, et al. Pharmacokinetics of olanzapine in Chinese male schizophrenic patients with various smoking behaviors. Prog Neuropsychopharmacol Biol Psychiatry 2008;32:1889-1893.
17. Mauri MC, Volonteri LS, Colasanti A, Fiorentini A, De Gaspari IF, Bareggi SR. Clinical pharmacokinetics of atypical antipsychotics: a critical review of the relationship between plasma concentrations and clinical response. Clin Pharmacokinet 2007;46:359-388. (Pubitemid 46686464)
18. Callaghan JT, Bergstrom RF, Ptak LR, Beasley CM. Olanzapine: pharmacokinetic and pharmacodynamic profile. Clinical Pharmacokinetics 1999;37:177-193. (Pubitemid 29452754)
19. Ghotbi R, Mannheimer B, Aklillu E, Suda A, Bertilsson L, Eliasson E, et al. Carriers of the UGT1A4 142T > G gene variant are predisposed to reduced olanzapine exposure: an impact similar to male gender or smoking in schizophrenic patients. Eur J Clin Pharmacol 2010;66:465-474.
20. Bergemann N, Frick A, Parzer P, Kopitz J. Olanzapine plasma concentration, average daily dose, and interaction with co-medication in schizophrenic patients. Pharmacopsychiatry 2004;37:63-68. (Pubitemid 38651019)
21. Citrome L, Stauffer VL, Chen L, Kinon BJ, Kurtz DL, Jacobson JG, et al. Olanzapine plasma concentrations after treatment with 10, 20, and 40mg/d in patients with schizophrenia: an analysis of correlations with efficacy, weight gain, and prolactin concentration. J Clin Psychopharmacol 2009;29:278-283.
22. Nozawa M, Ohnuma T, Matsubara Y, Sakai Y, Hatano T, Hanzawa R, et al. The relationship between the response of clinical symptoms and plasma olanzapine concentration, based on pharmacogenetics: Juntendo University Schizophrenia Projects (JUSP). Ther Drug Monit 2008;30:35-40. (Pubitemid 351161096)
23. Bottai T, Quintin P, Perrin E. Antipsychotics and the risk of diabetes: a general data review. Eur Psychiatry 2005;20(Suppl 4):S349-S357. (Pubitemid 43188782)
24. Baldessarini RJ, Tarazi FI. Drugs and the treatment of psychiatric disorders. 10th ed. New York: McGraw-Hill Medical Publishing Division; 2001.
25. Toren P, Ratner S, Laor N, Weizman A. Benefit-risk assessment of atypical antipsychotics in the treatment of schizophrenia and comorbid disorders in children and adolescents. Drug Saf 2004;27:1135-1156. (Pubitemid 39647854)
26. Baptista T, Beaulieu S. Are leptin and cytokines involved in body weight gain during treatment with antipsychotic drugs? Can J Psychiatry 2002;47:742-749. (Pubitemid 35345718)
27. Simon V, Van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry 2010;70:1041-1050.
28. Albaugh VL, Henry CR, Bello NT, Hajnal A, Lynch SL, Halle B, et al. Hormonal and metabolic effects of olanzapine and clozapine related to body weight in rodents. Obesity 2006;14:36-51. (Pubitemid 46214773)
29. Kassahun K, Mattiuz E, Nyhart E Jr., Obermeyer B, Gillespie T, Murphy A, et al. Disposition and biotransformation of the antipsychotic agent olanzapine in humans. Drug Metab Dispos 1997;25:81-93. (Pubitemid 27045138)
30. Markowitz JS, Devane CL, Liston HL, Boulton DW, Risch SC. The effects of probenecid on the disposition of risperidone and olanzapine in healthy volunteers. Clin Pharmacol Ther 2002;71:30-38. (Pubitemid 34124036)
31. Kassahun K, Mattiuz E, Franklin R, Gillespie T. Olanzapine 10-N-glucuronide: A tertiary N-glucuronide unique to humans. Drug Metab Dispos 1998;26:848-855. (Pubitemid 28452050)
32. Calligaro DO, Fairhurst J, Hotten TM, Moore NA, Tupper DE. The synthesis and biological activity of some known and putative metabolites of the atypical antipsychotic agent olanzapine. Bioorg Medicinal Chem Lett 1997;7:25-30. (Pubitemid 27008524)
33. Linnet K. Glucuronidation of olanzapine by cDNA-expressed human UDP-glucuronosyltransferases and human liver microsomes. Hum Psychopharmacol 2002;17:233-238. (Pubitemid 34823349)
34. Blevins-Primeau AS, Sun D, Chen G, Sharma AK, Gallagher CJ, Amin S, et al. Functional significance of UDP-glucuronosyltransferase variants in the metabolism of active tamoxifen metabolites. Cancer Res 2009;69:1892-1900.
35. Wiener D, Doerge DR, Fang JL, Upadhyaya P, Lazarus P. Characterization of N-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanol (NNAL) in human liver: importance of UDP-glucuronosyltransferase 1A4. Drug Metab Dispos 2004;32:72-79. (Pubitemid 38112538)
36. Coughtrie MW, Burchell B, Bend JR. A general assay for UDPglucuronosyltransferase activity using polar amino-cyano stationary phase HPLC and UDP[U-14C]glucuronic acid. Anal Biochem 1986;159:198-205. (Pubitemid 17228246)
37. Chen G, Dellinger RW, Gallagher CJ, Sun D, Lazarus P. Identification of a prevalent functional missense polymorphism in the UGT2B10 gene and its association with UGT2B10 inactivation against tobacco-specific nitrosamines. Pharmacogenetics and Genomics 2008;18:181-191. (Pubitemid 351323232)
38. Chen G, Dellinger RW, Sun D, Spratt TE, Lazarus P. Glucuronidation of tobacco-specific nitrosamines by UGT2B10. Drug Metab Dispos 2008;36:824-830. (Pubitemid 351574879)
39. Ren Q, Murphy SE, Zheng Z, Lazarus P. O-glucuronidation of the lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) by human UDP-glucuronosyltransferases 2B7 and 1A9. Drug Metab Dispos 2000;28:1352-1360.
40. Dellinger RW, Fang JL, Chen G, Weinberg R, Lazarus P. Importance of UDP-glucuronosyltransferase 1A10 (UGT1A10) in the detoxification of polycyclic aromatic hydrocarbons: decreased glucuronidative activity of the UGT1A10 139Lys isoform. Drug Metab Dispos 2006;34:943-949. (Pubitemid 43763749)
41. Sun D, Chen G, Dellinger RW, Duncan K, Fang JL, Lazarus P. Characterization of tamoxifen and 4-hydroxytamoxifen glucuronidation by human UGT1A4 variants. Breast Cancer Res 2006;8:R50.
42. Lazarus P, Blevins Primeau AS, Zheng Y, Sun D. Potential role of UGT pharmacogenetics in cancer treatment and prevention: Focus on tamoxifen. Ann N Y Acad Sci 2009;1155:99-111.
43. Chen G, Blevins-Primeau AS, Dellinger RW, Muscat JE, Lazarus P. Glucuronidation of nicotine and cotinine by UGT2B10: loss of function by the UGT2B10 codon 67 (Asp > Tyr) polymorphism. Cancer Res 2007;67:9024-9029. (Pubitemid 47535885)
44. Gallagher CJ, Muscat JE, Hicks AN, Zheng Y, Dyer A-M, Chase GA, et al. The UDP-glucuronosyltransferase 2B17 gene deletion polymorphism: sex-specific association with urinary 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol glucuronidation phenotype and risk for lung cancer. Cancer Epidemiol Biomarkers Prev 2007;16:823-828. (Pubitemid 46650589)
45. Devane CL, Markowitz JS. Antipsychotics. 1st ed. Ambler: Lippincott Williams & Wilkins; 2000.
46. Ehmer U, Vogel A, Schtte JK, Krone B, Manns MP, Strassburg CP. Variation of hepatic glucuronidation: novel functional polymorphisms of the UDP-glucuronosyltransferase UGT1A4. Hepatology 2004;39:970-977. (Pubitemid 38428936)
47. Wiener D, Fang JL, Dossett N, Lazarus P. Correlation between UDP-glucuronosyltransferase genotypes and 4-(methylnitrosamino)-1-(3-pyridyl) - 1-butanone glucuronidation phenotype in human liver microsomes. Cancer Res 2004;64:1190-1196. (Pubitemid 38176928)
48. Rowland A, Elliot DJ, Williams JA, Mackenzie PI, Dickinson RG, Miners JO. In vitro characterization of lamotrigine N2-glucuronidation and the lamotriginevalproic acid interaction. Drug Metab Dispos 2006;34:1055-1062. (Pubitemid 43763765)
49. Kaivosaari S, Toivonen Pi, Hesse LM, Koskinen M, Court MH, Finel M. Nicotine glucuronidation and the human UDP-glucuronosyltransferase UGT2B10. Molecular Pharmacology 2007;72:761-768. (Pubitemid 47347311)
50. Izukawa T, Nakajima M, Fujiwara R, Yamanaka H, Fukami T, Takamiya M, et al. Quantitative analysis of UDP-glucuronosyltransferase (UGT) 1A and UGT2B expression levels in human livers. Drug Metab Dispos 2009;37:1759-1768.
51. 2-estradiol and epiestradiol by human UDP- glucuronosyltransferases. Drug Metab Dispos 2008;36:2307-2315.
52. Chen G, Giambrone NE, Dluzen DF, Muscat JE, Berg A, Gallagher CJ, et al. Glucuronidation genotypes and nicotine metabolic phenotypes: importance of functional UGT2B10 and UGT2B17 polymorphisms. Cancer Res 2010;70:7543-7552.
53. Berg JZ, Mason J, Boettcher AJ, Hatsukami DK, Murphy SE. Nicotine metabolism in African Americans and European Americans: variation in glucuronidation by ethnicity and UGT2B10 haplotype. J Pharmacol Exp Therap 2010;332:202-209.
54. Berg JZ, von Weymarn LB, Thompson EA, Wickham KM, Weisensel NA, Hatsukami DK, et al. UGT2B10 genotype influences nicotine glucuronidation, oxidation, and consumption. Cancer Epidemiol Biomarkers and Prevent 2010;19:1423-1431.
55. *1F and serotonergic polymorphisms influence therapeutic outcome. Pharmacogenomics 2010;10:20-29.
56. Carrillo JA, Herraiz A, Ramos SI, Gervasini G, Vizcaino S, Benitez J. Role of the smoking-induced cytochrome P450 (CYP) 1A2 and polymorphic CYP2D6 in steady-state concentration of olanzapine. J Clin Psychopharmacology 2003;23:119-127.(Pubitemid 36368788)